Though perhaps true before, now that Vitiligo (which is further along in development) has the green light this is basically a non issue assuming Phase 3 confirms previous trials as expected.
Ann: SCENESSE provides photoprotection in variegate porphyria, page-9
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.78 |
Change
0.190(1.30%) |
Mkt cap ! $725.6M | |||
| Open | High | Low | Value | Volume |
| $14.76 | $14.96 | $14.46 | $770.9K | 52.43K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 272 | $14.73 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.76 | 82 | 5 |
View Market Depth
| Last trade - 13.40pm 31/07/2024 (20 minute delay) ? |
| CUV (ASX) Chart |